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Abstract 
Dementia is one of the major burdens of our aging society. According to certain predictions, the number of 
patients will double every 20 years. Although Alzheimer’s disease (AD), as the most frequent neurodegenera-
tive dementia, has been extensively analysed, less is known about dementia with Lewy bodies (DLB). Neuropa-
thological hallmarks of DLB are the deposition of intracellular Lewy bodies (LB) and Lewy neurites (LN). DLB 
belongs to the α-synucleinopathies, as the major component of these inclusions is pathologically aggregated α-
synuclein. Depending on the localization of LBs and LNs in the central nervous system cognitive and motor 
symptoms can occur. In our work, we will systematically review the possible etiology and epidemiology, patho-
logical (both macroscopic and microscopic) features, structural and functional imaging findings, with a special 
emphasis on the clinico-pathological correlations. Finally, we summarize the latest clinical symptoms-based 
diagnostic criteria and the novel therapeutic approaches. Since DLB is frequently accompanied with AD pathol-
ogy, highlighting possible differential diagnostic approaches is an integral part of our paper. Although our pre-
sent knowledge is insufficient, the rapid development of diagnostic and research methods provide hope for 
better diagnosis and more efficient treatment, contributing to a better quality of life. 
Keywords: α-synuclein, Biomarkers, Diagnostic criteria, Clinico-pathological correlation, Dementia with Lewy bodies 
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AA, Alzheimer’s Association; AD, Alzheimer’s dis-
ease; Aβ, Amyloid-beta; APOE, Apolipoprotein E gene; 
BNE, BrainNet Europe Consortium; BOLD, Blood oxygen 
level dependent; ChAT, Choline-acetyltransferase; ChAT-
I, Acetyl-cholinesterase inhibitors; CR, Creatinine; CSF, 
Cerebrospinal fluid; DLB, Dementia with Lewy bodies; 
DMN, Default mode network; DSM, Diagnostic Statistical 
Manual; fMRI, Functional MRI; FP-CIT, [123I] 2ß-
carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) 
nortropane; GBA, Glucosylceramidase-beta gene; iLBD, 
Incidental Lewy body disease; LB, Lewy-body; LBDA, 
Lewy Body Dementia Association; LN, Lewy neurite; 
MAPT, Microtubule associated protein tau gene; MDS, 
Movement Disorders Society; MRI, Magnetic resonance 
imaging; NAA, N-acetyl aspartate; NCD, Neurocognitive 
disorder; NF, Neurofilament; NIA, National Institute on 
Aging; NMDAR, N-methyl-D-aspartate receptor; PD, 
Parkinson’s disease; PDD, Parkinson’s disease dementia; 
PET, Positron emission tomography; PSD95, Density 
protein 95; REM, Rapid-eye-movement; SCARB2, Scav-
enger Receptor Class B Member 2; SNARE, SNAP (Solu-
ble NSF Attachment Protein) Receptor; SNCA, α-
synuclein gene; SPECT, Single-photon emission comput-
ed tomography; SSRI, Selective serotonin reuptake in-
hibitors; UPR, Unfolded protein response; WML, White 
matter lesions; ZnT3, Zinc transporter 3 
Epidemiology and etiology 
Dementia with Lewy bodies (DLB) is the second 
most common primary neurodegenerative dementia. 
The etiology is mainly unknown, however, in certain 
cases there is strong evidence of genetic background. A 
few papers have reported families with accumulating 
occurrence of cognitive impairment throughout genera-
tions1. The vast majority of the familial cases are traced 
to α-synuclein (SNCA) gene alterations, particularly to 
E46K mutation2. Five candidate genes, including APOE, 
GBA, MAPT, SNCA and SCARB2, are considered as a sig-
nificant risk factor for DLB, nevertheless, further genetic 
studies are needed3. Although it mostly appears in older 
age, dementia is not strictly associated with aging. Rare-
ly it may occur under the age of 65 and even in young 
adulthood. Surprisingly in the case report of a teenager, 
the clinical symptoms and post-mortem pathological 
findings were consistent with those of in DLB4. The prev-
alence of the disease is not clearly established. Accord-
ing to a comprehensive analysis of epidemiological data, 
the prevalence is 4.2% in community based and 7.5% in 
clinical studies, while the incidence is 3.8% and grows 
linearly with aging5, while the prevalence of DLB among 
patients with dementia is probably around 15%6. 
Pathologic background 
1. Macroscopic observation 
Many of the general pathologic features resemble 
those in Parkinson’s disease (PD). The brain weight is 
often within the normal limits, mild cortical atrophy of 
the frontal lobe, neuromelanin pigment loss in the sub-
stantia nigra and locus coeruleus are noted. In the case 
of severe concomitant AD pathology, atrophy of the 
temporal and parietal regions is more evident. In con-
trast to AD, the general brain atrophy is less prominent 
in DLB along with the relatively preserved temporal lobe 
and hippocampus7. 
2. Microscopic features 
Lewy bodies (LBs), the key pathological findings in 
DLB, were initially described by Friedrich Lewy in 19128. 
However, LBs are characteristic of other neurodegenera-
tive diseases including PD. Their typical appearance, 
stained with conventional hematoxylin-eosin, is a central 
spherical eosinophilic core surrounded by a peripheral 
halo situated intracellularly, causing dislocation of sub-
cellular organs. These features are regularly found in 
brainstem predominant LB formation. The rest of the 
brain expresses rather irregular LBs without the typical 
peripheral halo (Figure 1). 
Histopathologically, the dominant component of 
the central core is α-synuclein, while the peripheral halo 
consists of several ubiquitinated proteins9. Lewy neu-
rites (LNs), as an additional hallmark of α-
synucleinopathies, are abnormal thickened neurites 
containing filaments corresponding to those in LBs10. 
Interestingly, in experimental mouse models mutant 
SNCA inoculation of wild type mouse causes LB/LN-like 
pathology, supporting the pathognomonic role of the 
protein11. The background of LB genesis is still undiscov-
ered, although numerous hypotheses have been pro-
posed trying to explain the proper mechanism. Accord-
ing to the aggresome hypothesis, LB formation is origi-
nally a neuroprotective process, facilitating the cells to 
remove harmful proteins12. However, failure of the ag-
gresome formation may occur, leading to excessive LB 
development13. Other authors presume that autophagy 
dysfunction is responsible for the neuronal loss14. A 
recent study suggests that the increased unfolded pro-
tein response (UPR) activation has an important role in 
the LB pathology15. Nevertheless, according to Tompkins 
et al. neurons burdened with LBs are less apoptotic16. 
Moreover, the downregulation of tyrosine hydroxylase 
enzymes protects against toxic products of dopamine 
oxidation17. These findings confirm the theory that α-
synuclein is physiologically involved in the maintenance 
of cell homeostasis 
Free Neuropathology 1:7 (2020) János Bencze et al 
doi: https://doi.org/10.17879/freeneuropathology-2020-2613 page 3 of 12 
 
 
 
 
Figure 1. Dementia with Lewy bodies (DLB) specific pathologi-
cal changes are shown with hematoxylin and eosin (HE) stain-
ing (Panel A) and α-synuclein immunohistochemistry (ICH) 
(Panel B). Cortical-type Lewy bodies (LBs) are eosinophilic 
intracellar neuronal inclusions which dislocate the nucleus 
(Panel A, black star). α-synuclein IHC highlights LBs (white star, 
Panel B) and LNs (arrowhead, Panel B). 
 
The first standardized criterion assessing the con-
nections between pathological findings and DLB was 
made by Kosaka et al. in 1984. Based on the anatomical 
distribution of pathology they determined three differ-
ent subtypes: i) brainstem predominant LBs (commonly 
in PD) ii) limbic (transitional) LBs and iii) diffuse cortical 
LBs18. Later the Consortium on DLB International Work-
shop has improved the original assignment and pub-
lished a more detailed instruction emphasizing the im-
portance of the diagnostic procedure. The widely used 
immunohistochemical markers, α-synuclein (the most 
specific) and p62 serve the accurate pathological diagno-
sis19. The latest McKeith diagnostic consensus criteria 
recommends a semiquantitative grading of 10 different 
brain regions (dorsal motor nucleus of Vagus, locus co-
eruleus, substantia nigra, nucleus basalis of Meynert, 
amygdala, transentorhinal and cingulate gyri, temporal-, 
frontal- and parietal lobes) based on the lesion density 
instead of the previously used LB counting method. 
Moreover, it suggests two additional categories, the 
amygdala-predominant and the olfactory bulb only DLB. 
According to the distribution of LB pathology on α-
synuclein immunostained slides, the scoring system 
distinguishes four stages: 1 – mild (sparse LBs or LNs); 2 
– moderate (1< LBs in a low power field and sparse LNs); 
3 - severe (4≤ LBs and scattered LNs in a low power 
field); 4 – very severe (numerous LBs and numerous LNs). 
Finally, as a synthesis of score and localization it ranks 
the seen pathology into one out of the three previously 
mentioned subtypes20. Besides the McKeith staging and 
subtyping, the other widely used evaluating technique is 
the Braak staging21. The authors proposed to assess the 
severity of Lewy-type pathology labelled by α-synuclein 
immunostaining in 13 different brain areas (dorsal motor 
nucleus of Vagus, locus coeruleus, raphe, substantia 
nigra, CA2 region of hippocampus, nucleus basalis of 
Meynert, transentorhinal-, cingulate- and insular gyri, 
temporo-occipital-, temporal-, frontal- and parietal 
lobes). Considering that neither McKeith nor Braak pro-
tocol could reach more than 80% inter-observer agree-
ment; the original methods have been modified by Lev-
erenz et al.22 and Müller et al.23, respectively. However, 
their results did not lead to a significant improvement in 
the scoring systems. Thus, in 2009 the BrainNet Europe 
Consortium (BNE) revised their former assignments and 
suggested modifications, to reach a better inter-
observer agreement. Using the original McKeith and 
Braak staging, but eliminating their major pitfalls and 
obstacles as well as introducing the amygdala predomi-
nant category, BNE’s novel strategy resulted in above 
80% agreement in both typing and staging of α-synuclein 
pathology24. Beach et al. also published their unified 
staging system with the aim of dividing every subject 
with Lewy-type α-synuclein pathology into a well-
defined neuropathological group25. In 2009 they used 
McKeith26 and Braak21 staging systems and failed to 
categorize individuals with olfactory bulb or limbic-
predominant LB pathology. Investigating 10 standard 
brain regions they could classify all patients with PD, 
DLB, incidental Lewy body disease (iLBD) and AD with 
concomitant LB pathology into one of the following 
stages: I Olfactory Bulb Only; IIa Brainstem-
predominant; IIb Limbic-predominant; III Brainstem and 
Limbic; IV Neocortical. Moreover, they found strong 
correlation between the progression through these 
stages and the severity of nigrostriatal degeneration, 
cognitive impairment and motor dysfunction. It should 
be noted that olfactory bulb only and amygdala-
predominant subtypes are also included in the current 
McKeith criteria20. As mentioned above, AD pathology is 
frequently encountered in DLB. Approximately 80% of 
patients have diffuse amyloid-beta (Aβ) plaques and 60% 
have neurofibrillary tangles with varying severity in the 
entorhinal cortex and rarely in the neocortex. Some of 
these cases meet the pathological criteria of AD27. In 
contrast, “pure” neuropathological form of DLB is less 
common. Autopsy series suggest that the frequency of 
this entity is approximately 25% of all DLB cases28,29.
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LB pathology 
Alzheimer pathology NIA-AA/ Braak stage 
  
None, low / 
Braak 0-II 
Intermediate / Braak 
III-IV. High / Braak V-VI. 
Brainstem-predominant High High Intermediate 
Likelihood of 
DLB clinical 
syndrome 
Limbic (transitional) High Intermediate Low 
Diffuse neocortical Low Low Low 
Amygdala-predominant Low Low Low 
Olfactory bulb only Low Low Low 
 
Table 1. Likelihood of Dementia with Lewy bodies (DLB) clinical syndrome resulting from the assessment of Alzheimer’s-type and Lewy 
body pathology (LB= Lewy body; DLB=Dementia with Lewy bodies; NIA-AA = National Institute on Aging – Alzheimer’s Association) 
[Modified from McKeith et al.20] 
 
Theoretically, the likelihood to manifest DLB clinical 
syndrome is directly proportional to the severity of LB 
pathology and inversely proportional to the severity of 
AD pathology. The McKeith classification integrates the 
assessment of concomitant AD pathology by National 
Institute on Aging and Alzheimer’s Association (NIA-
AA)30, the Braak criteria and the type of LB pathology20. 
Table 1 shows the probability of pathological findings in 
relation to DLB clinical syndrome. It is likely that not only 
the α-synuclein pathology is responsible for the cogni-
tive decline, but plaques and phosphorylated tau pro-
teins also contribute to the overall deficit31. 
Cognitive impairment is also a common hallmark of 
DLB and Parkinson’s disease dementia (PDD). These two 
neurocognitive disorders share several clinical and neu-
ropathological features, i.e. they are both characterized 
by cortical and subcortical α-synuclein/LB, β-amyloid 
and tau pathologies32. 
According to Jellinger et al., a common pathophys-
iology in DLB and PDD is synaptic dysfunction due to 
aggregation of α-synuclein in the presynapses. This re-
sults in disruption of axonal transport and neurotrans-
mitter deprivation leading to neurodegeneration32. In-
terestingly, there are some morphologic differences as 
well. DLB seems to show higher load of β-amyloid and 
tau in several brain regions primarily in striatum, cortex, 
claustrum, amygdala and putamen compared to PDD32. 
Jellinger et al. also describes that α-synuclein distribu-
tion is different in DLB and PDD where α-synuclein load 
was highest in hippocampal subarea CA2 and in amygda-
la in DLB, whereas in PD it is highest in the cingulate 
cortex. Moreover, nigral neuronal loss is more marked in 
PDD which ultimately results in dopaminergic upregula-
tion32. A simple interpretation of above findings could 
support the current diagnostic criteria where DLB is 
associated with early cognitive impairment including 
memory problems, which differs from PDD with mainly 
motor impairment in the early phase. 
In reality, it is not easy to define DLB based upon 
only the histological findings, thus in uncertain cases, 
anamnestic clinical data has invaluable support for the 
diagnostics. It is important to highlight that the listed 
strategies are not absolute or perfect diagnostic criteria, 
but rather useful schemes to predict the clinical syn-
drome of DLB based on the observed pathological find-
ings. As mentioned above, a major weakness of current 
guidelines is the low inter-observer agreement; there-
fore further research is needed to assess the accuracy of 
the current clinical diagnostic criteria versus neuropa-
thology similar to studies assessing the 2005 criteria in 
this respect33. 
3. Synaptic alterations 
In connection with the dopaminergic neuronal loss 
of substantia nigra, dopamine transporter level is de-
creased in the striatum in DLB, although not to the same 
extent observed in PD34. The choline-acetyltransferase 
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(ChAT) levels are lower than in patients with AD, who 
suffer from similarly severe dementia35,36. Interestingly, 
Dynamin-1, which takes part in the regulation of synap-
tic transmission, shows significantly decreased levels in 
the prefrontal cortex in parallel with the severity of 
cognitive decline37. In addition, the amount of zinc 
transporter 3 (ZnT3) and postsynaptic density protein 95 
(PSD95), are significantly reduced in DLB compared to 
aged-controls and patients with AD38,39. It should be 
noted that at the beginning of the disease, an upregula-
tion of soluble NSF attachment protein receptors 
(SNARE) complex is observed, probably as a compensa-
tory response to the synaptic loss. However, during the 
progression of DLB synaptotagmin, synapsin and synap-
tophysin, proteins involved in the SNARE complex 
steadily disintegrate, contributing further to synaptic 
dysfunction40,41. Recent studies have revealed that more 
than 90% of α-synuclein aggregates are located at the 
presynapses leading to neurotransmitter deficits42,43. 
These findings suggest that degeneration of postsynaptic 
neurons may result from the loss of their inputs. This 
theory serves as a potential explanation for the DLB-
specific clinical symptoms as well as raises the possibility 
of future curative treatments by pharmaceutical modifi-
cation of neurotransmission. 
4. Incidental Lewy-body disease (iLBD) 
In iLBD, patients have histologically detectable α-
synuclein deposits in their brain, without presenting any 
clinical symptoms. Researchers accept that iLBD, which 
appears in approximately 8-17% of the clinically normal 
60+ years old patients, is the early stage of PD or 
DLB44,45. Confirming this hypothesis, it is frequently ob-
served in patients who represent the prodromes of PD, 
including olfactory dysfunction or bowel frequency46,47. 
The presence of neuronal loss is usually minimal in these 
cases contrary to PD or DLB48. Distribution of α-synuclein 
pathology in iLBD is particularly predictive, i.e. the brain-
stem predominant subtype frequently results in PD, 
while the cortical predominant subtype often leads to 
DLB44. 
Clinical symptoms 
The new Diagnostic Statistical Manual (DSM-5) 
(published in 2013) created a new neurocognitive disor-
der (NCD) group, replacing the former ‘dementia, deliri-
um, amnestic and other cognitive disorders’ category, 
that were used in the previous DSM-IV handbook. The 
definition emphasizes that NCD is a progressive, ac-
quired decline; which implies that disorders occurring at 
birth or at the early stage of cognitive development are 
excluded from this category. As an advantage, the new 
handbook removed the stigmatizing debilitating term, 
dementia. Within the NCD there are two subcategories: 
major and mild neurocognitive disorders based upon the 
severity of decline. For the diagnosis, six main fields are 
examined by DSM-5: complex attention, executive func-
tion, learning and memory, language, perceptual motor 
or social cognition49. 
In the case of DLB, patients show both cortical and 
subcortical progressive dementia symptoms. Character-
istic features comprise of attention and spatial percep-
tion disorder, dysexecutive syndrome, fluctuating cogni-
tive performance lasting from minutes to days. Among 
the psychiatric alteration the most frequent is the visual 
hallucination, although anxiety, apathy or organised 
delusions could also be detected.50,51. Interestingly, ad-
vanced cerebral amyloid angiopathy and small vessel 
disease are associated with psychosis in AD and not in 
DLB52. Depression is more common in patients with DLB 
than in patients with AD. It may accompany with mild 
dementia, although more frequent in cases of advanced 
DLB53,54. The vast majority of the patients, from the be-
ginning or during the progression, show extrapyramidal 
signs, such as action tremor, gait disturbances, rigidity or 
changes in facial expressions55. Rapid-eye-movement 
(REM) parasomnia is frequently diagnosed in DLB, char-
acterised by vivid, often frightening dreams and complex 
purposeful motor activity. Since it often appears in dif-
ferent neurodegenerative disorders, REM parasomnia 
might be an early herald of these diseases56. In DLB the 
autonomic nervous system dysfunction is more severe 
than in AD. Patients usually complain of dizziness, falls or 
loss of consciousness. Orthostatic hypotension, cardio-
inhibitory carotid sinus hypersensitivity and urinary 
incontinency often accompany with DLB57. Pathogno-
monic feature is the neuroleptic hypersensitivity, trig-
gered by even a small dose of drug, leading to severe 
parkinsonism20. A 5-year prospective cohort study pub-
lished by Rongve et al. has reported that the progression 
of cognitive decline from mild to severe stage is more 
rapid in patients with DLB than in patients with AD58. 
Many clinical symptoms of DLB cannot be ex-
plained only by the intracerebral localization of LBs and 
LNs33. Neurotransmitter depletion, synaptic alterations, 
concomitant AD-type pathology and metabolic changes 
highly influence the clinical presentation of DLB, and 
correlate with the severity of cognitive decline6,42,59,60. 
Moreover, a recent paper has reported association of 
serum potassium levels with cognitive decline in DLB, 
specifically in patients not using any medications that 
affect serum K+ levels61. Reduced perfusion and dyscon-
nectivity of the occipital lobe may contribute to visual 
hallucinations and disturbance of visuospatial orienta-
tion62,63. REM sleep behavior disorder (RBD) is also asso-
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ciated with striatal dopamine depletion64. Vegetative 
dysfunctions (i.e. orthostatic hypotension) may result 
from the deposition of LBs in the autonomic ganglia65. 
Decreased ZnT3 levels were also identified in patients 
with depression, providing a novel therapeutic tar-
get38,66. Interestingly, several clinical symptoms of DLB 
are transient in nature, however LBs and LNs perma-
nently occur in the brain. Probably, metabolic disturb-
ances67, hormonal alterations68, circadian rhythm69 and 
comorbidities such as high blood pressure70 can affect 
the clinical appearance of DLB. 
Radiologic features 
Besides the clinical symptoms, the most significant 
diagnostic tool in the identification of DLB is the rapidly 
developing imaging techniques. The numerous reacha-
ble modalities allow both structural and functional ex-
amination. 
Magnetic resonance imaging (MRI) examination 
Regarding the structural changes, the literature is 
not consistent: some studies have noted significant at-
rophy of the insular, frontal, inferior parietal, temporal 
or occipital cortex71, whereas others have found only a 
minimal volumetric decrease in the frontal and parietal 
lobe, or in the territory of hypothalamus, basal forebrain 
and midbrain 72. However, these alterations are not 
specific to DLB and might appear in AD. Although differ-
entiation from AD is usually based on the absence of 
medial temporal atrophy, its presence cannot rule out 
the diagnosis of DLB73. Sabattoli et al. have found 
atrophic changes in the anterior CA1, CA2/3 hippocam-
pus, subiculum and presubiculum in DLB. This pattern 
differs significantly from those in AD74. According to an 
MRI study, the annual progression rate of cortical atro-
phy is approximately 2x higher in patients with AD72. The 
role of white matter lesions (WML) in DLB, including loss 
of myelin, axonal damage and gliosis is not consistent. 
Presumably, WMLs are implicated in vascular dementia 
rather than being specific feature of neurodegenerative 
disorders75. MRI spectroscopy provides a chance to indi-
rectly assess the neuronal and glial function by measur-
ing the key metabolites. N-acetyl aspartate (NAA) and 
creatinine (CR) are two widely used markers in the char-
acterization of central nervous system metabolism. Wat-
son et al. have found that the NAA/CR ratio is relatively 
preserved in DLB in comparison to in AD76. 
Functional imaging 
Although, task-related functional MRI (fMRI) has 
been performed in very few cases of DLB, a paper has 
reported reduced activity in response to movement 
activity compared with aged controls and patients with 
AD77. Alternatively, researchers have examined the func-
tional activity during rest. The resting-state network 
shows increased activity during rest and decreased activ-
ity during cognitive tasks. The most investigated resting-
state network to date is the default mode network 
(DMN), including prefrontal cortex, posterior cingulate 
gyrus, medial temporal lobe and precuneus. In these 
areas the task-related deactivation during the colour and 
motion tasks were decreased in DLB, but it was not sig-
nificantly different from AD78. A technique for evaluation 
of functional resting state connectivity is based on the 
functional alterations in blood oxygen level dependent 
(BOLD) activity. Galvin et al. have noted increased rest-
ing state connectivity between precuneus seeding re-
gions, inferior parietal cortex and putamen, with de-
creased connectivity between medial prefrontal, fron-
toparietal operculum and visual cortex79. Taking into 
account that the results in DLB significantly differed from 
those of in AD, the method can be considered in the in 
vivo differential diagnosis. 
The real value of perfusion imaging techniques in 
the identification of DLB is not fully consistent. The vast 
majority of the authors described occipital hypoperfu-
sion as a hallmark of the disease on single-photon emis-
sion computed tomography (SPECT) images, whereas 
the specificity of the method is variable depending on 
the study80. [123I] 2ß-carbomethoxy-3b-(4-iodophenyl)-
N-(3-fluoropropyl) nortropane (FP-CIT) could be useful 
to discover DLB in early stages before the full spectrum 
of clinical symptoms evolve, moreover it reliably identi-
fies neurobiological changes in the dopaminergic sys-
tem81. In DLB there is markedly reduced tracer uptake in 
the regions of caudate and putamen reflecting the se-
verely affected dopaminergic system. Strong connection 
has been found between striatal FP-CIT uptake and cer-
tain clinical symptoms, such as depression, anxiety, apa-
thy and daytime somnolence82. 
Positron emission tomography (PET) is probably a 
more sensitive functional imaging technique than SPECT 
in different dementias. Ishii et al. have compared the 
two methods and found that PET is more reliable in the 
detection of occipital and parietal lobe hypometabo-
lism83. Besides the dopaminergic system, cholinergic 
transmission also has a crucial role in the pathomecha-
nism of DLB, for instance in the alteration of memory, 
attention or arousal. Significant cholinergic neuronal loss 
and reduced ChAT activity are noted extensively in the 
cortical and subcortical regions, including both nicotin-
ergic and muscarinergic systems, compared to AD36. 
Shimada et al. have shown reduced ChAT enzymatic 
activity in the medial occipital cortex with relatively 
preserved temporal activity in DLB, in contrast to AD84. 
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The fact that EEG is involved in the McKeith criteri-
on further justifies its diagnostic relevance. Compared to 
AD the detectable slower background activity and more 
diffuse slow-wave activity probably reflect the severe 
cholinergic deficit in DLB85. 
Biomarkers 
It is difficult to find specific biomarkers of DLB that 
would allow us to discriminate neuropathologically 
‘pure’ forms of the disease from cases with concomitant 
AD pathology86, as that majority of DLB cases show a 
combination of α-synuclein, tau and β-amyloid patholo-
gies87,88. However, novel biomarkers such as reduced 
electroencephalography activity89 and the detection of 
RBD90 also have some value. 
Recent DLB biomarker research has focused on 
targets that are primarily related to AD. As in AD, CSF 
levels of Aβ1-42 are decreased in DLB91, although tau 
seems to show an opposite relationship from AD92. That 
said tau has been shown to be higher in DLB when com-
pared to PD and PDD87,93,94. 
DLB is considered α-synucleinopathy alongside 
with PD and PDD. When α-synuclein was discovered as a 
major component of LB this initiated a string of studies 
investigating α-synuclein as a biomarker in CSF95,96. In 
general, some groups have reported reduced α-
synuclein97,98 while others have shown contradictory 
results99,100. These discrepancies may arise from the 
nature of α-synuclein expression. α-synuclein appears in 
four isoforms, (α-syn98, α-syn112, α-syn126 and α-
syn140), based on alternative splicing of exon 3 and 5, 
and the largest isoform, α-syn140, is the most abundant 
isoform in the brain101,102. Nonetheless, to overcome this 
issue several groups have tried using a combination of 
antibodies to quantify ‘total’ α-synuclein103. In addition 
to this, many are convinced that oligomeric α-synuclein 
is potentially a more pathogenic form104 and efforts have 
been made to measure this in both CSF and in plasma105–
107. 
In addition to α-synuclein and AD biomarkers, oth-
er potential biomarkers such as neurofilaments (NF) 
have been investigated108. NFs are components within a 
cell that assists in maintaining the structural integrity. It 
has been shown that NFs are associated with AD and 
other degenerative disorders109–111, however that is not 
the case with DLB. NFs seem to provide only a general 
hint of neuronal and axonal dysfunction without provid-
ing any differential value to separate DLB from other 
disorders. On the other hand, other isoforms of NFs112 
do exist and would have to be further investigated in 
DLB. 
Since there is greater involvement of the dopamin-
ergic and serotonergic neurotransmitters in DLB com-
pared to AD, several groups have investigated metabo-
lites from these pathways. In combination with CSF Aβ1-
42, reduced levels of 5- hydroxyindolacetic acid and 3- 
methoxy-4-hydroxyphenylethyleneglycol have been 
found in DLB compared with AD104,113. 
In summary, current studies suggest that DLB is in-
termediate to AD and PD, such that biomarkers from AD 
and PD have been tested in DLB with moderate suc-
cess114. Likewise, new diagnostic proteins may be dis-
covered in the future with further proteomic studies 
which could provide a better differentiation of DLB from 
other closely related neurodegenerative disorders115–117. 
Diagnostic criteria 
Considering the heterogeneous phenotype and the 
frequently associated AD pathology, the clinical symp-
tom-based diagnosis of DLB is rather difficult. To date, 
there is no consensus on the guidelines for assessing 
clinical symptoms of DLB. A recent paper58 recommends 
the following rating strategies: for evaluating cognitive 
decline – Clinical Dementia Rating scale118; for estimat-
ing fluctuating cognition – Clinician Assessment of Cogni-
tive Fluctuations119 or Mayo Fluctuation Question-
naire120; for investigating REM parasomnia - Mayo Sleep 
Questionnaire121; for rating parkinsonism – Unified Par-
kinson’s Rating Scale122; for testing disability - Rapid 
Disability Rating Scale-2123; for diagnosing visual halluci-
nations or other psychiatric disorders – Neuropsychiatric 
Inventory124; for measuring effects of comorbidities – 
Cumulative Illness Rating Scale118. Additional difficulty is 
to make a distinction, if it exists, between DLB and Par-
kinson’s disease dementia. The question, whether DLB 
and PDD are different entities or the same one, is still 
debated. Although there are a few morphologic differ-
ences between them (e.g. cortical spreading of LBs or 
rate of neuronal loss in SN)125, differential diagnosis is 
rather based on the temporal sequence of symptoms. If 
dementia occurs 1 year after the onset of extrapyrami-
dal motor signs, it is considered as PDD, otherwise if 
dementia has proceeded or presented within 1 year 
after movement disorder, the diagnosis should be 
DLB126. The latest McKeith diagnostic criteria define 
probable and possible DLB based on the clinical symp-
toms and biomarkers (Figure 2)20. The presence of de-
mentia, memory impairment and deficit of attention, 
executive functions and visuospatial orientation is essen-
tial for diagnosis. Core symptoms are frequently ob-
served in DLB clinical syndrome; in the lack of at least 
one core feature, the probable DLB diagnosis
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Figure 2.: Symptoms and biomarkers contribute to the diagnosis of probable or possible Dementia with Lewy bodies (DLB). 
Essential symptoms are mandatory for diagnosis of DLB. Core clinical symptoms are characteristic to DLB, while supportive symptoms 
can confirm the decision by clinicians. Indicative biomarkers are frequently observed in DLB, while supportive biomarkers can facilitate 
the decision-making procedure. Important to note that clinicians cannot establish the diagnosis of probable DLB based on the bi-
omarkers. (Recategorized or newly added features are highlighted in blue colour; REM = Rapid eye movement; DAT = Dopamine trans-
porter; MIBG = Metaiodobenzylguanidine; PSG = Polysomnography; RBD = REM sleep behavior disorder; SPECT = Single-photon emis-
sion computed tomography; PET = Positron-emission tomography; EEG = Electroencephalography; ↓ = decrease). [Adapted from 
McKeith et al.20] 
 
 
cannot be established. The development of diagnostic 
techniques revealed that REM sleep behaviour disorder 
is more characteristic of LBD than it was previously 
thought. Therefore, McKeith et al. recategorized RBD 
from supportive to core features20. Supportive features 
may help the clinicians; however, these symptoms are 
not specific to DLB and their presence is not required for 
the diagnosis of neither probable nor possible DLB. The 
refreshed criteria emphasize the importance of disease-
specific biomarkers. One indicative biomarker itself is 
sufficient for possible DLB diagnosis. If one indicative 
biomarker associates with one core symptom, the diag-
nosis is probable DLB. 
Therapy 
There are two different therapeutic approaches: 
pharmacologic and non-pharmacologic. Although there 
is no curative treatment strategy, the adequate therapy 
may slow the disease progression with the chance of a 
better quality of life. 
Non-pharmacologic interventions 
At the first signs of DLB or mild NCD, installation of 
the below mentioned interventions are recommended. 
Changes in the dietary habit, Mediterranean diet, and 
regularly performed social and mental tasks as well as 
physical activities could reduce the rate of progres-
sion127. Personalized cognitive rehabilitation trainings 
with focus on the declined field, improve both quality of 
life and memory128. 
Pharmacologic treatments 
The frequently noted extrapyramidal signs should 
be treated with the smallest effective dose of levodopa, 
to avoid the worsening of psychiatric symptoms129. Se-
lective serotonin reuptake inhibitors (SSRIs) are widely 
used and considered as effective medications for de-
pression130. In the case of REM sleep behaviour disorder, 
clonazepam and melatonin also have beneficial effect131 
Acetyl-cholinesterase inhibitors (ChAT-I) have benefits in 
the treatment of psychiatric disturbances such as visual 
hallucination, delusions, behaviour disorders or apathy. 
Despite gastrointestinal side effects (i.e. vomiting, diar-
rhoea) these drugs are usually well tolerated20. If ChAT-Is 
(rivastigmine, donepezil) are not effective, the use of 
atypical neuroleptic drugs (i.e. clozapine) might be inevi-
table, but typical neuroleptics should be avoided to 
minimize the possibility of severe neuroleptic hypersen-
sitivity reaction132. ChAT-Is are more effective in patients 
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with DLB compared to patients with AD. These drugs 
improve the cognitive functions, reduce fluctuation, 
decrease the progression and in addition patients score 
better on neuropsychological tests133. N-methyl-D-
aspartate receptor (NMDA-R) antagonist memantine is 
also useful in the treatment of cognitive decline134. Lucza 
et al. have suggested treatment with ChAT-Is in mild or 
mid-severe dementia and memantine combined with 
high dose of rivastigmine (13.5 mg) in severe demen-
tia135. 
Summary 
Despite the continuously growing incidence of de-
mentia, which could be the most prevalent disease with-
in 20 years in the industrialized world, our present 
knowledge is still insufficient to fully comprehend the 
underlying pathomechanism. This is particularly true for 
DLB, which is the second most common neurodegenera-
tive dementia. Etiology of the disorder, its connection 
with aging, underlying pathomechanisms of clinical signs 
and imaging findings are still in need for further elucida-
tion. Unfortunately, the definitive diagnosis is possible 
only by post-mortem histopathological examination and 
not by in vivo techniques (apart from a low percentage 
of cases). The concomitant Alzheimer’s-type and vascu-
lar pathology raises issues regarding diagnostic clarity 
and accuracy136. Future research should be multidiscipli-
nary and should include pathological, proteomic, genetic 
and epigenetic approaches to identify the key factors of 
the disease and reveal the correlation between clinical 
symptoms, radiological alterations and pathological 
findings. Development of imaging techniques brings the 
possibility of in vivo diagnosis, which implies adequate 
treatments in early stages, a crucial advancement to 
ensure better quality of life. Longitudinal cohort studies 
are also required to provide detailed prognostic infor-
mation that are essential for planning a more effective 
and cost-efficient treatment protocol. 
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